Extracorporeal heparin adsorption following cardiopulmonary bypass with a heparin removal device - An alternative to protamine

Critical Care Medicine

Volumn 26, Issue 6, 1998, Pages 1096-1102

  Tao, Weike ^a   Deyo, Donald J ^a   Brunston Jr , Robert L ^a   Vertrees, Roger A ^a   Zwischenberger, Joseph B ^a  

^a University of Texas Medical Branch School of Medicine   (United States)

Author keywords

Cardiopulmonary bypass; Extracorporeal circulation; Heparin; Poly L lysine; Protamine; Swine

Indexed keywords

HEMOGLOBIN; HEPARIN; INFUSORIAL EARTH; KAOLIN; POLYLYSINE; PROTAMINE;

ADSORPTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD CLOTTING TIME; CARDIOPULMONARY BYPASS; CENTRAL VENOUS PRESSURE; CONTROLLED STUDY; DEVICE; EXTRACORPOREAL CIRCULATION; FEMALE; HEART RATE; HEPARINIZATION; LUNG ARTERY PRESSURE; MEAN ARTERIAL PRESSURE; NONHUMAN; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; SWINE;

ADSORPTION; ANIMALS; ANTICOAGULANTS; BLOOD COAGULATION; CARDIOPULMONARY BYPASS; EXTRACORPOREAL CIRCULATION; FEMALE; HEMODYNAMIC PROCESSES; HEPARIN; PROTAMINES; SWINE;

EID: 0031776349     PISSN: 00903493     EISSN: None     Source Type: Journal    
DOI: 10.1097/00003246-199806000-00035     Document Type: Article

References (39)

1. Levy JH: Anaphylactic/anaphylactoid reactions during cardiac surgery. J Clin Anesth 1989; 1:426-430
2. Weiler JM, Gellhaus MA, Carter JG, et al: A prospective study of the risk of an immediate adverse reaction to protamine sulfate during cardiopulmonary bypass surgery. J Allergy Clin Immunol 1990; 85:713-719
3. Lowenstein E, Zapol WM: Protamine reactions, explosive mediator release, and pulmonary vasoconstriction. Anesthesiology 1990; 73:373-375
4. Weiler JM, Freiman P, Sharath MD, et al: Serious adverse reactions to protamine sulfate: Are alternatives needed? J Allergy Clin Immunol 1985; 75: 297-303
5. Al-Mondhiry H, Pierce WS, Basarab RM: Protamine-induced thrombocytopenia and leukopenia. Thromb Haemost 1985; 53:60-64
6. Click RL, Homburger HA, Bove AA: Complement activation from protamine sulfate administration after coronary angiography. Cathet Cardiovasc Diagn 1989; 16:221-225
7. Ma X, Mohammad SF, Kim SW: Heparin removal from blood using poly (L-lysine) immobilized hollow fiber. Biotechnol Bioeng 1992; 40:530-536
8. Vertrees RA, Zwischenberger JB, McRea JC, et al: Reversal of anticoagulation without protamine using a heparin removal device after cardiopulmonary bypass. ASAIO J 1994; 40:M560-M564
9. Tao W, Callahan JD, Vertrees RA, et al: Heparin clearance profiles following systemic anticoagulation using a heparin removal device system. ASAIO J 1997; 43:922-926
10. Bjornsson TD: Clinical pharmacology of heparin. In: Recent Advances in Clinical Pharmacology. Turner P, Shand DG (Eds). Edinburgh, Churchill Livingstone, 1983, pp 129-155
11. Wakefield TW, Lindblad B, Stanley TJ, et al: Heparin and protamine use in peripheral vascular surgery: A comparison between surgeons of the Society for Vascular Surgery and the European Society for Vascular Surgery. Eur J Vasc Surg 1994; 8:193-198
12. Moorman RM, Zapol WM, Lowenstein E: Neutralization of heparin anticoagulation. In: Cardiopulmonary Bypass: Principles and Practice. Gravlee GP, Davis RF, Utley JR (Eds). Baltimore, Williams & Wilkins, 1993, pp 381-406
13. Nyhan DP, Shampaine EL, Hirshman CA, et al: Single doses of intravenous protamine result in the formation of protamine-specific IgE and IgG antibodies. J Allergy Clin Immunol 1996; 97:991-997
14. Hobbhahn J, Conzen PF, Habazettl H, et al: Heparin reversal by protamine in humans - Complement, prostaglandins, blood cells, and hemodynamics. J Appl Physiol 1991; 71:1415-1421
15. Morel DR, Zapol WM, Thomas SJ, et al: C5a and thromboxane generation associated with pulmonary vaso- and broncho-constriction during protamine reversal of heparin. Anesthesiology 1987; 66:597-604
16. Best N, Teisner B, Grudzinskas JG, et al: Classical pathway activation during an adverse response to protamine sulphate. Br J Anaesth 1983; 55: 1149-1153
17. Sugi K, Esato K: Effect of a thromboxane synthetase inhibitor on protamine-induced circulatory changes in sheep. Surgery 1993; 114:586-590
18. Morel DR, Costabella PM, Pittet JF: Adverse cardiopulmonary effects and increased plasma thromboxane concentrations following the neutralization of heparin with protamine in awake sheep are infusion rate-dependent. Anesthesiology 1990; 73:415-424
19. 2 release from the lung. Am J Surg 1987; 154: 696-699
20. Horiguchi T, Enzan K, Mitsuhata H, et al: Heparin-protamine complexes cause pulmonary hypertension in goats. Anesthesiology 1995; 83:786-791
21. Nuttall GA, Murray MJ, Bowie EJ: Protamine-heparin-induced pulmonary hypertension in pigs: Effects of treatment with a thromboxane receptor antagonist on hemodynamics and coagulation. Anesthesiology 1991; 74: 138-145
22. Montalescot G, Lowenstein E, Ogletree ML, et al: Thromboxane receptor blockade prevents pulmonary hypertension induced by heparin-protamine reactions in awake sheep. Circulation 1990; 82:1765-1777
23. Vollmar B, Conzen PF, Habazettl H, et al: Heparin-protamine reactions in pigs: Role of oxygen-derived free radicals. J Appl Physiol 1993; 74:2412-2420
24. Cho PW, Gillinov AM, Zehr KJ, et al: Neutrophil activation mediates protamine-induced pulmonary hypertension. J Surg Res 1993; 54:486-493
25. Akata T, Kodama K, Takahashi S: Effects of heparin on the inhibitory action of protamine on endothelium-mediated vasorelaxation. Acta Anaesthesiol Scand 1995; 39:698-704
26. Wakefield TW, Bies LE, Wrobleski SK, et al: Impaired myocardial function and oxygen utilization due to protamine sulfate in an isolated rabbit heart preparation. Ann Surg 1990; 212: 387-394
27. Hird RB, Spinale FG, Hewett KW, et al: The direct effects of protamine sulfate on myocyte contractile processes. J Thorac Cardiovasc Surg 1994; 108:1100-1114
28. Park WK, Pancrazio JJ, Lynch C, 3rd: Mechanical and electrophysiological effects of protamine on isolated ventricular myocardium: Evidence for calcium overload. Cardiovasc Res 1994; 28: 505-514
29. Pearson PJ, Evora PR, Ayrancioglu K, et al: Protamine releases endothelium-derived relaxing factor from systemic arteries. A possible mechanism of hypotension during heparin neutralization. Circulation 1992; 86:289-294
30. Raikar GV, Hisamochi K, Raikar BL, et al: Nitric oxide inhibition attenuates systemic hypotension produced by protamine. J Thorac Cardiovasc Surg 1996; 111:1240-1247
31. Yang VC, Port FK, Kim JS, et al: The use of immobilized protamine in removing heparin and preventing protamine-induced complications during extracorporeal blood circulation. Anesthesiology 1991; 75:288-297
32. Bernstein H, Yang VC, Lund D, et al: Extracorporeal enzymatic heparin removal: Use in a sheep dialysis model. Kidney Int 1987; 32:452-463
33. Byun Y, Yun JH, Han IS, et al: A protamine filter for extracorporeal heparin removal. Development, testing, blood compatibility evaluation, and future direction. ASAIO J 1995; 41: M301-M305
34. 2. Biochim Biophys Acta 1996; 1300:226-232
35. Jusko WJ, Evans WE, Schentag JJ: Applied Pharmacokinetics: Principles of Therapeutic Drug Monitoring. San Francisco, Applied Therapeutics, 1980, pp 618-638
36. Conti VR, Vertrees RA, Zwischenberger JB, et al: First clinical use of a heparin removal device: An alternative to protamine. J Thorac Cardiovasc Surg 1995; 109:1015-1017
37. Gelb AB, Roth RI, Levin J, et al: Changes in blood coagulation during and following cardiopulmonary bypass: Lack of correlation with clinical bleeding. Am J Clin Pathol 1996; 106:87-99
38. Seydewitz HH, Witt I: Increased phosphorylation of human fibrinopeptide A under acute phase conditions. Thromb Res 1985; 40:29-39
39. Hawkey CJ, Stirling Y, Chakrabarti R, et al: Haemostatic changes following surgery. Thromb Res 1983; 32: 223-227